At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 84 enrolled
Drug / intervention
Brimonidine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)
In Brief
A Phase 2 clinical trial evaluating Brimonidine, Brimonidine Mono Therapy, and 2 other interventions for Dry Eye. Completed, enrolled 84 participants across 3 sites.
Detailed Summary
To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
First PostedFeb 2018
Primary CompletionMar 2018
TodayJul 2026
First PostedFeb 1, 2018
Enrollment StartSep 6, 2017
Primary CompletionMar 29, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.4 years ago
Interventions
Brimonidinedrug
Two products delivered in sequence twice daily.
Brimonidine Mono Therapydrug
Brimonidine given twice daily along with placebo drops
sodium carboxymethylcellulosedrug
Placebo given twice daily.
Corticosteroid Eye Dropdrug
Eye drop to be administered after Brimonidine in treatment arm 1